Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ≥ 65 Years of Age With and Without Zostavax Vaccination at Least 5 Years Earlier

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 137173A (Primary)
Indications Herpes zoster
Focus Adverse reactions; Pharmacodynamics; Registrational
Acronyms Zoster-048
Sponsors GlaxoSmithKline; GSK

Most Recent Events

27 Feb 2020 Results from post-hoc analyses on the correlation between humoral and CMI responses and polyfunctional CD4 T-cell responses published in the Journal of Infectious Diseases
07 Oct 2018 Results presented at the IDWeek 2018
08 Oct 2017 Primary endpoint (Anti-glycoprotein E (Anti-gE) Antibody (Ab) Concentrations-non-inferiority) has been met, according to results presented at the IDWeek 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com